Somma Lombardo, Italy

Gianluca Caprini

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Italfarmaco Spa. Active years: 2022.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gianluca Caprini: Innovator in Selective HDAC6 Inhibitors

Introduction

Gianluca Caprini is a notable inventor based in Somma Lombardo, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of selective HDAC6 inhibitors. His work focuses on creating novel compounds that exhibit high selective inhibitory activity against the histone deacetylase 6 (HDAC6) enzyme.

Latest Patents

Gianluca Caprini holds a patent for selective HDAC6 inhibitors. The patent details novel benzohydroxamic compounds of formula (I) and (II), along with their pharmaceutically acceptable salts, isomers, and prodrugs. These compounds are designed to provide therapeutic benefits by selectively inhibiting the HDAC6 enzyme.

Career Highlights

Gianluca Caprini is associated with Italfarmaco Spa, a company known for its commitment to research and development in the pharmaceutical industry. His work at Italfarmaco Spa has allowed him to focus on innovative solutions that address critical health challenges.

Collaborations

Gianluca collaborates with talented professionals in his field, including Barbara Vergani and Gianluca Fossati. These collaborations enhance the research and development efforts at Italfarmaco Spa, fostering an environment of innovation.

Conclusion

Gianluca Caprini is a prominent figure in the pharmaceutical industry, recognized for his innovative work on selective HDAC6 inhibitors. His contributions are paving the way for new therapeutic options in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…